| Literature DB >> 25857232 |
Tae Hwan Kim1, Sun Dong Yoo1, Hye Suk Lee2, Kyoung Mee Lee3, Su Hyun Seok1, Min Gi Kim1, Byung Hwa Jung4, Min Gyu Kim1, Beom Soo Shin5.
Abstract
This study aimed to evaluate the potential of α-cedrene as a new anti-obesity drug by characterizing absorption, metabolism and pharmacokinetics in rats. α-Cedrene was administered intravenously (10 and 20 mg/kg) and orally (50 and 100 mg/kg) to female and male Sprague-Dawley rats. Blood, tissues, urine, and feces were collected at predetermined times. α-Cedrene concentrations were determined by a validated gas chromatography-tandem mass spectrometry (GC-MS/MS). A gas chromatography-mass selective detection (GC-MSD) method was used to identify the major metabolite. After i.v. injection, α-cedrene exhibited a rapid clearance (98.4-120.3 ml/min/kg), a large distribution volume (35.9-56.5 l/kg), and a relatively long half-life (4.0-6.4 h). Upon oral administration, it was slowly absorbed (Tmax = 4.4 h) with bioavailability of 48.7-84.8%. No gender differences were found in its pharmacokinetics. Upon oral administration, α-cedrene was highly distributed to tissues, with the tissue-to-plasma partition coefficients (Kp) far greater than unity for all tissues. In particular, its distribution to lipid was notably high (Kp = 132.0) compared to other tissues. A mono-hydroxylated metabolite was identified as a preliminary metabolite in rat plasma. These results suggest that α-cedrene has the favorable pharmacokinetic characteristics to be further tested as an anti-obesity drug in clinical studies.Entities:
Keywords: Bioavailability; Elimination; Obesity; Pharmacokinetics; Tissue distribution; α-cedrene
Mesh:
Substances:
Year: 2014 PMID: 25857232 DOI: 10.1016/j.dmpk.2014.12.003
Source DB: PubMed Journal: Drug Metab Pharmacokinet ISSN: 1347-4367 Impact factor: 3.614